-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Maresca defends Chelsea rotation policy after Rooney criticism
-
Hundreds of flights cut across US in government paralysis
-
Xhaka 'made me a better coach', says Arsenal boss Arteta
-
Central Nigerian town rebuilds religious trust in shadow of Trump's threat
-
Inside Germany's rare earth treasure chest
-
Former jihadist Syrian leader makes unprecedented White House visit
-
Kagiyama takes NHK lead in Japan to kick-start Olympic season
-
Ikea profits drop on lower prices, tariff costs
-
European, Asian stocks decline after Wall Street slide
-
Tuchel brings 'immense' Bellingham and Foden back into England fold
-
German FA extends with president Neuendorf until 2029
-
No end to Sudan fighting despite RSF paramilitaries backing truce plan
-
US officials, NGOs cry foul as Washington snubs UN rights review
-
Injured teen medal hope Tabanelli risks missing home Winter Olympics
-
Bellingham, Foden recalled to England squad for World Cup qualifiers
-
Tanzania rights group condemns 'reprisal killings' of civilians
-
Slot urges patience as Isak returns to training with Liverpool
-
Rees-Zammit set for Wales return with bench role against Argentina
-
China's new aircraft carrier enters service in key move to modernise fleet
-
Operation Cloudburst: Dutch train for 'water bomb' floods
-
Leaders turn up the heat on fossil fuels at Amazon climate summit
-
US travel woes mount as govt shutdown prompts flight cuts
-
North Korea fires unidentified ballistic missile: Seoul military
-
West Bank's ancient olive tree a 'symbol of Palestinian endurance'
-
Global tech tensions overshadow Web Summit's AI and robots
-
Green shines as Suns thump Clippers 115-102
-
Japan to screen #MeToo film months after Oscar nomination
-
Erasmus relishing 'brutal' France re-match on Paris return
-
Rejuvenated Vlahovic taking the reins for Juve ahead of Turin derby
-
'Well-oiled' Leipzig humming along in Bayern's slipstream
-
Bangladesh cricket probes sexual harassment claims
-
NFL-best Broncos edge Raiders to win seventh in a row
-
Deadly Typhoon Kalmaegi ravages Vietnam, Philippines
-
Three killed in new US strike on alleged drug boat, toll at 70
-
Chinese microdrama creators turn to AI despite job loss concerns
-
Trump hails Central Asia's 'unbelievable potential' at summit
-
Kolya, the Ukrainian teen preparing for frontline battle
-
Big leap in quest to get to bottom of climate ice mystery
-
Markets drop as valuations and US jobs, rates spook investors
-
'Soap opera on cocaine': how vertical dramas flipped Hollywood
-
Under pressure? EU states on edge over migrant burden-sharing
-
US influencers falsely associate Mamdani with extremist group
-
Hungary's Orban to meet Trump in face of Russia oil sanctions
-
US facing travel chaos as flights cut due to govt shutdown
-
Liverpool and Man City renew rivalry as they try to narrow Arsenal gap
-
UK's Andrew asked to testify over Epstein as he formally loses titles
-
Local hero: 'DC sandwich guy' found not guilty of assaulting officer with sub
-
Dead famous: Paris puts heritage graves up for grabs
-
UK grandmother on Indonesia death row flies home
US drug regulator limits use of J&J Covid vaccine
The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition.
The vaccine, which was authorized as a single shot, is less protective than those developed by Pfizer and Moderna, and in December the Centers for Disease Control and Prevention advised the public to steer clear.
Thursday's decision by the Food and Drug Administration builds on that recommendation by limiting the J&J vaccine's emergency use authorization.
"Today's action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions," said FDA scientist Peter Marks in a statement.
Sixty US cases of thrombosis with thrombocytopenia syndrome (TTS), which produces rare and potentially life-threatening blood clots with low levels of blood platelets, had been reported by March 18, with nine deaths.
Symptoms begin approximately one to two weeks following administration, and the condition -- which can cause life-long impacts even when not fatal -- occurs more frequently in premenopausal women.
Concerns over the vaccine have already limited uptake: Only 18.7 million doses have been administered in the United States, or about 3.2 percent of the total 577 million.
But the FDA stopped short of an outright de-authorization, with Marks acknowledging the impact a ban might have on global use of the vaccine, as well as concerns some may have specifically against mRNA vaccines, rather than the adenovirus vector platform J&J uses.
There are certain health-based justifications for not taking an mRNA vaccine -- such as rare instances of heart inflammation in adolescent males and young men -- although these are usually transient in nature and the vast majority affected recover completely.
However, anti-vaccine groups have also raised more general objections against mRNA vaccines, which are tied to conspiracy theories.
Although those types of concerns are not rooted in evidence, the exemption to use J&J's shot nonetheless extends to "individuals who have personal concerns with receiving mRNA vaccines and would otherwise not receive a Covid-19 vaccine," the FDA's statement said.
P.Martin--AMWN